Heme Oxygenase 1‐Targeted Hybrid Nanoparticle for Chemo‐ and Immuno‐Combination Therapy in Acute Myelogenous Leukemiaopen access
- Authors
- Yong, Seok-Beom; Kim, Jaehyun; Chung, Jee Young; Ra, Sehee; Kim, Seong Su; Kim, Yong-Hee
- Issue Date
- Jul-2020
- Publisher
- WILEY
- Keywords
- acute myelogenous leukemia; cancer immunotherapy; heme oxygenase 1-targeted leukemia immunotherapy; heme oxygenase 1-targeted nanomedicine; immunotherapeutic nanomedicine
- Citation
- ADVANCED SCIENCE, v.7, no.13, pp.1 - 14
- Indexed
- SCIE
SCOPUS
- Journal Title
- ADVANCED SCIENCE
- Volume
- 7
- Number
- 13
- Start Page
- 1
- End Page
- 14
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/145369
- DOI
- 10.1002/advs.202000487
- Abstract
- Acute myelogenous leukemia (AML) is a fatal blood cancer with high patient mortality. Daunorubicin and cytarabine are first-line chemotherapy for AML, with bone marrow transplantation in most cases. Recently, cancer immunotherapy has been challenged in AML and leukemia-niche myeloid cells are promising targets for the AML immunotherapy. Heme oxygenase 1 (HO1) is an antioxidative and cytoprotective enzyme inducing chemo-resistant AML and has been focused as an immune checkpoint molecule in tumor microenvironments. Herein, lipid-polymer hybrid nanoparticle (hNP) is loaded with tin mesoporphyrin (SnMP), a HO1-inhibitor, and non-covalently modified with an engineered antibody for leukemic cell-targeted delivery. HO1-inhibiting T-hNP (T-hNP/SnMP) enhances chemo-sensitivity in human leukemia cells. In a human AML-bearing orthotopic mouse model, intravenously injected T-hNP not only actively targets to human leukemia cells but passively targets to CD11b+ myeloid cells in a bone marrow niche. The T-hNP/SnMP enhances the chemo-therapeutic effect of daunorubicin and boosts immune response by reprogramming bone marrow myeloid cells resulting from the recruitment of the monocyte-lineage and induction of inflammatory genes. The ex vivo study demonstrates an enhanced immune response of HO1-inhibited bone marrow CD11b+ myeloid cells against apoptotic leukemia cells. Collectively, HO1-inhibiting dual cell-targeted T-hNP/SnMP has a strong potential as a novel therapeutic in AML.
- Files in This Item
-
- Appears in
Collections - 서울 공과대학 > 서울 생명공학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/145369)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.